Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis

Journal of Rheumatology

Volumn 34, Issue 6, 2007, Pages 1277-1282

  Beall, Ashley D ^a,b   Nietert, Paul J ^a   Taylor, Marian H ^a   Mitchell, Holly C ^a   Shaftman, Stephanie R ^a   Silver, Richard M ^a   Smith, Edwin A ^a   Bolster, Marcy B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

African American; Ethnic groups; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; ILOPROST; OXYGEN; PROSTACYCLIN; SITAXSENTAN; TREPOSTINIL; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; DIASTOLE; DISEASE ASSOCIATION; DISEASE DURATION; ETHNIC DIFFERENCE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 34250197266     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gredinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase 1 are associated with increased severity of scleroderma lung disease. Chest 1998;114:801-7.
2. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase 1 antibody. Arthritis Rheum 1999;42:465-74.
3. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunologic determinants. Semin Arthritis Rheum 2001;30:332-46.
4. Mayes MD. Scleroderma Epidemiology. Rheum Dis Clin North Am 1996;22:751-64.
5. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
6. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
7. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21:467-74.
8. Morgan JM, Griffiths M, du Bois RM, Evans TW. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991;99:551-6.
9. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. Chest 1997;111:36-43.
10. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978;64:998-1004.
11. Steen V, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
12. Schachna L, Wigley FM, Chang B, White B, Wise A, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
13. Laing TG, Gillespie BW, Toth MD, et al. Racial difference in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
14. LeRoy EC, Black C, Fleishmajer R, et al. Scleroderma (systemic sclerosis): classification, subjects, and pathogenesis. J Rheumatol 1988;15:202-5.
15. rd ed. Baltimore: Williams & Wilkins; 1994: 941.
16. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
17. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-7S.
18. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology Oxford 2001;40:453-9.
19. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003;30:2398-405.
20. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62;1088-93.
21. Wigley FM, Lima JAC, Mayes M, McLain D, Chapin L, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.
22. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology Oxford 2004;43:461-6.
23. Badesch DB, Abman SH, Ahern GS, et al. Medical therapy for pulmonary arterial hypertension. Chest 2004;126:35S-62S.
24. Katsetos MC, Foley R, Silverman D, Rothfield N, Alkotob L, Hager WD. Etiology of dypsnea in systemic sclerosis. American Thoracic Society International Conference, 2005, abstract K56.
25. Nakajima K, Taki J, Kawano M, et al. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: an early sign of cardiac involvement. J Nucl Med 2001;42:183-8.
26. Aguglia G, Sgreccia A, Bernardo MR, et al. Left ventricular diastolic function in systemic sclerosis. J Rheumatol 2001;28:1563-7.
27. Plazak W, Zabinska-Plazak E, Wojas-Pele, et al. Heart structure and function in systemic sclerosis. Eur J Dermatol 2002;12:257-62.